Prospects and challenges for the development of new therapies for Ewing sarcoma
- 18 October 2012
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 137 (2) , 216-224
Abstract
No abstract availableKeywords
This publication has 112 references indexed in Scilit:
- A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomasEuropean Journal of Cancer, 2012
- Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: A predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomasEuropean Journal of Cancer, 2012
- Systematic identification of genomic markers of drug sensitivity in cancer cellsNature, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Dose escalation of intravenous irinotecan using oral cefpodoxime: A phase I study in pediatric patients with refractory solid tumorsPediatric Blood & Cancer, 2011
- Initial testing of topotecan by the pediatric preclinical testing programPediatric Blood & Cancer, 2010
- Initial testing of a monoclonal antibody (IMC‐A12) against IGF‐1R by the pediatric preclinical testing programPediatric Blood & Cancer, 2010
- A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcomaNature Medicine, 2009
- Phase II study of intermediate‐dose cytarabine in patients with relapsed or refractory Ewing sarcoma: A report from the Children's Oncology GroupPediatric Blood & Cancer, 2009
- Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi‐modality therapy: A report from the Children's Oncology GroupPediatric Blood & Cancer, 2008